# Data Sheet (Cat.No.T2534)

TargetMol

## Pitavastatin calcium

### Chemical Properties



CAS No. : 147526-32-7

Formula: C50H46CaF2N2O8

Molecular Weight: 880.98

Appearance: no data available

Storage: keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### Biological Description

| | |
|---|---|
| Description | Pitavastatin calcium (NK-104) is a potent inhibitor of HMG-CoA reductase (Ki: 1.7 nM). It lowers both total cholesterol and low-density lipoprotein cholesterol in animals and humans. Metabolism of pitavastatin by the cytochrome P450 system is minimal, reducing the risk of drug-drug interactions. |
| Targets(IC50) | Apoptosis,Mitophagy,Endogenous Metabolite,HMG-CoA Reductase,Autophagy |
| In vivo | Pitavastatin inhibits the progression of arterial atherosclerosis by blocking the synthesis of thromboxane and suppressing the migration or proliferation of vascular smooth muscle induced by angiotensin II, thereby stabilizing atherosclerotic plaques. It significantly reduces the levels of intracellular and synthesized cholesteryl esters. Moreover, pitavastatin enhances the extracellular expression of LDL receptors and increases the binding of LDL to LDL receptors. Compared to simvastatin and atorvastatin, pitavastatin is more effective in inducing the expression of LDL receptor mRNA. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 50 mg/mL (56.75 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.1351 mL | 5.6755 mL | 11.351 mL |
| 5 mM | 0.227 mL | 1.1351 mL | 2.2702 mL |
| 10 mM | 0.1135 mL | 0.5675 mL | 1.1351 mL |
| 50 mM | 0.0227 mL | 0.1135 mL | 0.227 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ahmad H, et al. Cardiol Rev, 2010, 18(5):264-267.
Zhang W, Pan X, Xu Y, et al.Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA.Acta Pharmaceutica Sinica B.2023
Martin G, et al. J Clin Invest, 2001, 107(11), 1423-1432.
Ohnaka K, et al. Biochem Biophys Res Commun, 2001, 287(2), 337-342.
Olsson AG, et al. Cardiovasc Drug Rev. 2002, 20(4):303-28.



Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481